Expected vs Actual Outcomes of Elective Initiation of Inotropic Therapy During Heart Failure Hospitalization

David Snipelisky, MD; Marat Fudim, MD, MHS; Antonio Perez, MD; Matthew Nayor, MD, MPH; Natasha M. Lever, CNP; David S. Raymer, MD, MPH; Andrew N. Rosenbaum, MD; Omar AbouEzzeddine, MDCM, MS; Adrian F. Hernandez, MD; Lynne Warner Stevenson, MD; and Lauren G. Gilstrap, MD, MPH

Abstract

Objective: To describe the intent and early outcomes of elective inotrope use during heart failure hospitalization.

Patients and Methods: A prospective multisite design was used to collect data for hemodynamically stable patients started electively on inotrope therapy between January 1 and August 31, 2018. We prospectively recorded data when intravenous inotropic therapy was initiated, including survey of the attending cardiologists regarding expectations for the clinical course. Patients were followed up for events through hospital discharge and an additional survey was administered at the end of hospitalization.

Results: For the 92 patients enrolled, average age was 60 years and ejection fraction was 24% ± 12%. At the time of inotrope initiation, attending heart failure cardiologists predicted that 50% (n = 46) of the patients had a “high or very high” likelihood of becoming dependent on intravenous inotropic therapy and 58% (n = 53) had a “high” likelihood of death, transplant, or durable ventricular assist device placement within the next 6 months. Provider predictions regarding death/hospice or need for continued home infusions were accurate only 51% (47 of 92) of the time. Only half the patients (n = 47) had goals-of-care conversations before inotrope treatment initiation.

Conclusion: More than half the patients (51 of 92) electively started on inotrope treatment without present or imminent cardiogenic shock ultimately required home inotrope therapy, died during admission, or were discharged with hospice. Heart failure clinicians could not reliably identify those patients at the time of inotrope therapy initiation and goals-of-care discussions were not frequently performed.

Several large registry studies have demonstrated increased morbidity and mortality in patients treated with intravenous inotropic therapies (IITs) in the inpatient setting. Such patients experience more arrhythmias, longer lengths of stay, increased in-hospital mortality, higher readmission rates, and increased costs.3–8 However, none of these registries separate elective initiation as adjunctive therapy (ie, to augment diuresis) from the more common initiation as urgent therapy for progressive hemodynamic decompensation. Although much is known about the prognosis and outcomes of hemodynamically
unstable patients started on IIT for cardiogenic shock, little is known about the prognosis of hemodynamically stable patients with HF started on IIT, typically for inadequate responses to standard decongestion strategies. Given the increasing use of inotropes in the inpatient setting and the increased diuretic resistance among contemporary hospitalized patients with HF, it is imperative that HF specialists and general cardiologists understand the implications and outcomes of starting IIT in hemodynamically stable patients. The aim of this study is to describe the anticipated/predicted and actual outcomes of hemodynamically stable patients with HF electively initiated on IIT in the inpatient setting.

PATIENTS AND METHODS

We used a prospective multicenter design to investigate hemodynamically stable patients with HF electively initiated on IIT from 6 academic medical centers across the United States between January 1 and August 1, 2018. Adult patients admitted to the hospital for a primary diagnosis of acute decompensated HF who were electively initiated on IIT during the admission were eligible for inclusion in the study. Elective initiation of IIT was defined as the initiation of inotropic therapy to assist with diuresis, not to treat hemodynamic instability or critical dysfunction of vital organs. None of the patients had clinical evidence of cardiogenic shock and were rather initiated on inotrope treatment with the intent to assist with diuresis. Patients initiated on IIT for reasons other than HF were excluded and concomitant diagnoses that can affect hemodynamics, including sepsis, acute coronary syndromes, and pulmonary embolism, were used as exclusion criteria. Study patients were identified using institution-specific clinical resources, including continual inpatient provider notifications of study criteria throughout the enrollment period and electronic investigator notifications within the electronic medical record when new orders for inotropes were placed. Patients with preexisting mechanical circulatory support devices or who required treatment with dual inotropes or temporary mechanical circulatory support for worsening cardiogenic shock were excluded.

At the time of IIT initiation, the clinical team managing each patient was asked to complete a questionnaire assessing various parameters including perceived likelihood of inotrope dependence and need for advanced therapies evaluation within the first 24 hours of inotrope treatment initiation. A second questionnaire was provided at time of discharge or death assessing patient outcomes and discharge disposition. Using electronic medical records, we collected clinical information at the time of admission and discharge for all patients.

For ease of comparison, β-blocker dosing was converted to daily metoprolol succinate equivalents. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and angiotensin receptor neprilysin inhibitor therapies were converted to daily lisinopril equivalents. Mineralocorticoid receptor antagonist therapies were converted to daily spironolactone equivalents. Loop diuretic regimens were converted to daily furosemide equivalents. All conversions were based on previously published algorithms. Advanced therapies were defined as cardiac transplantation, inpatient transplant listing, or durable mechanical circulatory support device placement.

Three groups were compared: (1) patients discharged without inotropes, (2) patients discharged with inotropes, and (3) patients who died or were discharged on hospice. Normality was determined using the Shapiro-Wilk test. For normally distributed continuous variables, we present mean ± SD values. For non-normally distributed continuous variables, we present values as median and interquartile range. For categorical variables, we present values as frequency. To compare variable frequency between patients discharged alive and off IIT with those discharged with home IIT, discharged to hospice, or who died before discharge, analysis of variance was used for continuous variables and \( \chi^2 \) test was used for proportional data.

We created 2 multivariable logistic regression models to determine the association between the attending cardiologists’ prediction regarding short-term outcomes and patients’ actual short-term outcomes. The 2 outcomes analyzed in these models were: (1) the frequency of inotrope dependence, and (2) a combined outcome of death, ventricular assist device (VAD) implantation, or transplantation in the subsequent 6 months. A coefficient of
The assessments of the attending HF cardiologist survey at inotrope initiation and discharge/death are presented in Table 3. Fifty percent (n=46) of patients were thought to have a “high” or “very high” likelihood of long-term IIT dependence. Fifty-eight percent (n=53) of patients were thought to have a “high” likelihood of death/VAD/cardiac transplant within the next 6 months. Interestingly, neither of these varied significantly by the patient’s ultimate outcome. Despite the prediction of poor outcomes, only 51% of patients (n=47) had a “goals-of-care” conversation before IIT initiation, with no significant variance by ultimate outcome. A total of 53% of patients (n=49) underwent formal advanced therapy evaluation during the index admission and 29% (n=27) went on to receive a VAD during the index admission, 10% (n=9) were listed for transplant, and 3% (n=3) underwent cardiac transplant during the index admission. Palliative care was involved in the care of only 61% of patients (56 of 92) initiated on inotrope treatment, but they were involved in the care of 87% (21 of 24) of those who ultimately died or were discharged with hospice care.

The Figure demonstrates physicians’ predictions regarding patient outcomes at the time of IIT initiation in comparison to the actual outcomes of patients. To determine whether physicians’ predictions regarding outcomes at the time of IIT initiation were associated with patient outcomes, we performed multivariable regression (Table 4). We found that a provider’s prediction of a poor prognosis at the time of IIT initiation was not significantly associated with poor outcomes for that patient. To further quantify the “added value” of the attending providers’ prediction, a multivariable outcome model with and without the attending providers’ prediction was created. The addition of the attending providers’ prediction increased the $R^2$ of the model by only 0.5% (from 32.2% to 32.7%), suggesting that the explanatory power gained by adding the attending providers’ clinical prediction to the other clinical variables in the model is minimal.

**DISCUSSION**

The goal of this multicenter prospective observational study was to describe the relationship
between anticipated and actual outcomes of hemodynamically stable patients initiated on IIT to augment diuresis. In this study of 92 patients across 6 academic medical centers, we found that 29% of patients (n = 27) ultimately required home IIT and 26% of patients (n = 24) either died or were discharged with hospice care. Only 53% of patients (n = 49) were discharged alive and without inotropes. Moreover, the attending providers’ predicted

TABLE 1. Patient Characteristics at Admission

| Demographic characteristic                   | Alive Off | Home | Death or Hospice |
|-----------------------------------------------|-----------|------|------------------|
| Age (y), mean ± SD                            | 60±12     | 59±13| 61±11            | 62±11            |
| Male sex, %                                   | 67        | 59   | 70               | 71               | .123
| HF cause, %                                   |           |      |                  |
| Ischemic HF                                   | 33        | 33   | 30               | 46               | .821
| Nonischemic HF                                | 67        | 67   | 70               | 54               |
| Comorbid condition, %                         |           |      |                  |
| Coronary artery disease                       | 34        | 35   | 30               | 46               | .984
| Hypertension                                  | 62        | 67   | 56               | 54               | .361
| Diabetes                                      | 43        | 51   | 30               | 38               | .119
| Chronic kidney disease                        | 50        | 53   | 44               | 46               | .531
| Atrial fibrillation/flutter                   | 58        | 57   | 59               | 63               | .747
| History of ventricular tachycardia            | 29        | 24   | 33               | 29               | .0391
| Implantable cardioverter defibrillator in place| 58        | 59   | 56               | 54               | .744
| Echocardiography parameter                    |           |      |                  |
| Left ventricular ejection fraction (%)        |           |      |                  |
| median (IQR)                                  | 20 (15-28)| 20 (15-28)| 20 (15-25)| 25 (16-33)| .688
| Left ventricular end-diastolic diameter (mm)  | 61 (50-70)| 59 (50-66)| 63 (48-71)| 60 (46-72)| .653
| Moderate/severe right ventricle dysfunction, %| 62        | 67   | 63               | 63               | .361
| Admission medications                         |           |      |                  |
| Admission β-blocker, %                       | 75        | 73   | 85               | 70               | .766
| Average dose (mg/d), median (IQR)             | 38        | 35   | 48               | 29               | .480
| Admission ACEi/ARB/ARNI, %                    | 38        | 35   | 48               | 29               | .480
| Average dose (mg/d), median (IQR)             | 5 (5-10)  | 6.5 (5.2-10) | 6.5 (5-40) | 5 (2.5-10) | .051
| Admission mineralocorticoid receptor antagonist, %| 52        | 53   | 59               | 38               | .686
| Average dose (mg/d), median (IQR)             | 25        | 25   | 25               | 25               | .842
| Admission loop diuretic use, %                | 84        | 78   | 100              | 83               | .089
| Average dose (mg/d), median (IQR)             | 80        | 80   | 80               | 80               | .471
| Admission examination data                   |           |      |                  |
| Systolic blood pressure (mm Hg), mean ± SD    | 105±16    | 110±17| 98±14            | 103±12           | .001
| Heart rate (beats/min), mean ± SD             | 89±23     | 90±25| 91±22            | 88±19            | .948
| Weight (kg), mean ± SD                       | 87±21     | 88±22| 82±18            | 87±21            | .618
| Admission laboratory data                    |           |      |                  |
| Sodium (mg/dL), median (IQR)                  | 137 (134-139)| 137 (135-140)| 137 (134-139)| 135 (134-139)| .385
| Creatinine (mg/dL), median (IQR)              | 1.5 (1.2-2.2)| 1.5 (1.2-2.1)| 1.3 (1.2-2.2)| 1.7 (1.3-2.5)| .452
| Serum urea nitrogen (mg/dL), median (IQR)     | 35 (24-54)| 34 (23-52)| 27 (24-45) | 42 (27-57) | .446
| NT-proBNP (pg/mL), mean ± SD                 | 9336±8417 | 8267±8012| 10,558±9587    | 11,125±8330     | .200

\*ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; HF = heart failure; IQR = interquartile range.

\*SI conversion factors: To convert sodium values to mmol/L, multiply by 1.0; to convert creatinine values to μmol/L, multiply by 88.4; to convert serum urea nitrogen values to mmol/L, multiply by 0.357; to convert NT-proBNP values to pmol/L, multiply by 0.118.

\*Eight patients were discharged home with hospice care and palliative inotrope therapy.

\*Medication dosing equivalents were used, with β-blocker dosing converted to daily metoprolol succinate equivalent; ACEi, ARB, and ARNI converted to daily lisinopril equivalent; mineralocorticoid receptor antagonist converted to daily spironolactone equivalent; and loop diuretic converted to daily furosemide equivalent.

\*Statistically significant.
EVALUATION OF INPATIENT OUTCOMES

TABLE 2. Clinical Characteristics at Inotrope Initiation and During Inotrope Therapya

|                              | All (N=92) | Alive Off Inotropes (n=49) | Home Inotropesb (n=27) | Death or Hospiceb (n=24) | P  |
|------------------------------|------------|---------------------------|------------------------|-------------------------|----|
| Inotrope choice              |            |                           |                        |                         |    |
| Milrinone, %                 | 46         | 51                        | 30                     | 54                      | .463|
| Dobutamine, %                | 43         | 41                        | 59                     | 25                      |    |
| Dopamine, %                  | 11         | 8                         | 11                     | 21                      |    |
| Concurrent drug use          |            |                           |                        |                         |    |
| β-Blockers, %                | 7          | 6                         | 4                      | 8                       | .865|
| ACEi/ARB/ARNI, %             | 8          | 10                        | 4                      | 4                       | .316|
| Mineralocorticoid receptor antagonist, % | 25    | 31                        | 26                     | 8                       | .184|
| Loop diuretic, %             | 86         | 88                        | 85                     | 79                      | .579|
| Pulmonary artery catheter use|            |                           |                        |                         |    |
| Right heart catheterization before inotrope start, % | 63 | 67                        | 85                     | 38                      | .361|
| Pulmonary artery catheter-guided therapies, % | 79 | 82                        | 81                     | 63                      | .563|
| Outcomes                     |            |                           |                        |                         |    |
| Arrhythmia (new or worsening), % | 33 | 35                        | 33                     | 42                      | .802|
| Intensive care unit admission/transfer, % | 63 | 69                        | 56                     | 46                      | .178|
| Days on inotrope (inpatient), mean ± SD | 11±12 | 11±11                      | 12±12                  | 11±11                   | .906|

aACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor.
bEight patients were discharged home with hospice care and palliative inotropes.
cComparing those discharged alive off inotrope therapy with the 2 other groups (home inotropes plus death or hospice).

outcomes were not significantly associated with patients’ actual outcomes. Despite the high rate of poor outcomes and limited ability of clinical characteristics and attending providers to predict the patients most likely to have poor outcomes, only 51% of patients (n=47) had conversations about their goals of care documented before inotrope treatment initiation. Considering that inotrope use is becoming a more frequent adjunct to medical therapy in patients with decompensated HF, it is important to understand its prognostic significance, particularly in a “healthier” population. Providers should understand the potential downstream effect of such medications and consider the difficulty predicting clinical outcomes at the time of initiation. Although inotropes have benefit in select patients, it is important to realize the uncertainty that may result.

Providers estimated that approximately 50% of patients (n=46) would require home IIT or experience death/VAD/transplant within the next 6 months. Although the clinicians were accurate at predicting the rate of adverse outcomes, they were not able to discriminate which patients were more or less likely to have them. Provider expectations were not associated with actual patient outcomes. However, multivariable modeling explained only 32% of the variability in outcomes between patients. This suggests that there is a tremendous amount of variability in outcomes between hemodynamically stable patients initiated on IIT that is not explained by traditional clinical risk factors or attending providers’ expectations. This presents significant challenges for case management and care coordination teams seeking to identify and help the patients most likely to experience poor outcomes and may be one reason that such programs have often not proved successful or financially viable in the past.

Despite clinical trials indicating no benefit or even increased risk with inotrope use in patients with HF, inpatient initiation of inotrope therapy remains high. Analysis of Get With the Guidelines—Heart Failure found a stable rate of inotrope use from 2007 to 2011 of approximately 6.1%, with marked variation between centers. A 2007 study by Elkayam et al that reviewed 433 patients from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) found that inpatient inotrope use was the strongest predictor of mortality
or rehospitalization, with a hazard ratio of 1.96 (95% CI, 1.37 to 2.82; \( P < .001 \)). Another reanalysis of ESCAPE by Kalogeropoulos et al found that inotrope use was associated with a higher rate of major events regardless of HF cause or systolic blood pressure. Notably, ESCAPE was not limited to hemodynamically stable patients, as this study is. However, in the almost 15 years since ESCAPE, the hospitalized HF population has evolved and we found that despite limiting our study to hemodynamically stable patients, the rates of adverse events were similarly high. Moreover, as seen in ESCAPE, systolic blood pressure was associated with patient outcomes. When we explored the variable further, we found that a threshold of 100 mm Hg was most predictive of patient outcomes, suggesting that patients with a “normal HF blood pressure” of 80 to 100 mm Hg may be at increased risk for adverse events if started on IIT, even if this occurs in the setting of hemodynamic stability to augment diuresis.

The present study also examined various clinical factors at the time of inotrope treatment initiation and found that they were not strongly associated with patient outcomes. Although 33% of patients (30 of 92) experienced a new or worsening arrhythmia with the initiation of IIT, there was no difference in the frequency of arrhythmias across the various outcomes.

Furthermore, as compared with earlier studies but similar to additional recent work, we found low rates of guideline-directed therapies. Less than half (n = 35) the patients were on angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor nephrin inhibitor therapy, about half (n = 48) were on mineralocorticoid receptor antagonists and three-fourths (n = 69) were on \( \beta \)-blockade at admission, before any inotrope treatment initiation. This is likely reflective of an overall higher-risk population yet confirms recent data from the Heart Failure Apprenticeship Network research group demonstrating that guideline-directed therapies are unfortunately not often optimized in many patients with HF and emphasizes the need to perhaps push the “guideline-directed medical therapy envelope” a bit farther in this new sicker hospitalized HF population.

Finally, we contend that these findings have significant implications for advanced care planning. The high rate of poor outcomes coupled with the limited ability of clinical variables and attending physicians to predict

| TABLE 3. Attending Physician Survey at Inotrope Initiation and Dischargea |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                 | All (\( N = 92 \)) | Alive Off Inotropes (\( n = 49 \)) | Home Inotropes\(^1\) (\( n = 27 \)) | Death or Hospice\(^2\) (\( n = 24 \)) | \( P ^c \) |
| Inotrope Initiation Survey      |                 |                 |                 |                 |                 |
| Anticipated outcomes            |                 |                 |                 |                 |                 |
| High/very high likelihood of inotrope dependence, % | 50 | 49 | 48 | 54 | .835 |
| Expected duration of inotrope therapy (d), mean ± SD | 7 ± 5 | 6 ± 5 | 6 ± 2 | 8 ± 7 | .694 |
| Sick enough for advanced therapy evaluation now, % | 77 | 71 | 85 | 79 | .161 |
| High likelihood of death/VAD/transplant within 6 mo, % | 58 | 57 | 59 | 58 | .923 |
| Advanced care planning at time of inotrope initiation |                 |                 |                 |                 |                 |
| Goals-of-care conversation before inotrope start, % | 51 | 47 | 59 | 46 | .396 |
| Hospitalization disposition     |                 |                 |                 |                 |                 |
| Advanced therapy outcomes       |                 |                 |                 |                 |                 |
| Formal advanced therapy evaluation done during admission, % | 53 | 51 | 63 | 48 | .722 |
| Received VAD during same admission, % | 29 | 39 | 15 | 25 | .034 |
| Listed for transplant during same admission, % | 10 | 16 | 4 | 0 | .024 |
| Underwent transplant during same admission, % | 3 | 2 | 0 | 8 | .482 |
| Advanced care planning during hospitalization |                 |                 |                 |                 |                 |
| Palliative care consultation/involved during hospitalization, % | 61 | 46 | 78 | 87 | .002 |

\(^{a}\)VAD = ventricular assist device.  
\(^{b}\)Eight patients were discharged home with hospice care and palliative inotrope therapy.  
\(^{c}\)Comparing those discharged alive off inotropes with the 2 other groups (home inotropes plus death or hospice).
patients most at risk underscores the need for goals of care to be defined explicitly before any inotrope therapy, even when initiated in hemodynamically stable patients. In addition to recognition of the potential for in-hospital death or discharge with hospice, consideration needs to be made regarding the difficulty of discontinuation of IIT during transition to hospice. In this study of 6 academic medical centers, despite house staff/resident teams and robust ancillary staff support, only 51% of patients (n=47) had goals of care discussed before inotrope initiation. This highlights an area with tremendous potential for quality and clinical improvement. Considering that goals of care tend to change during critical periods within a hospitalization, continued advanced care planning throughout the entirety of a hospital admission is warranted among this population.14

Although this study is limited primarily by its small sample size, it provides important new information about the serious implications of IIT even when started “electively” or to “augment diuresis” in hemodynamically stable patients. It prospectively combines patients from 6 different academic medical centers that are geographically spread across the United States, reflecting many different practice styles and institutional practices. However, the small sample size limits our ability to perform subgroup analyses. In addition, the attending HF cardiologists’ expectation may have been limited by inadequate time to consider all data relevant to prognosis. It is also important to note that because the study was performed at 6 centers, some attending HF cardiologists may have contributed to questionnaires for more than 1 patient in the study. However, these constraints reflect real-world practices in which decisions may be even more limited in the absence of the heightened awareness associated with a research study. In the context of relatively frequent use of inotropes in patients with decompensated HF, our study sheds light to the prognostic significance of its use, highlights provider inability to accurately predict outcomes, and ultimately supports the need for a pragmatic clinical trial to better understand these relationships.

**TABLE 4. Association Between Provider Prediction of Poor Outcome and Patients’ Rates of Poor Outcomes (death/hospice)**

| Anticipated high likelihood of inotrope dependence | Odds Ratio | 95% Lower Confidence Limit | 95% Upper Confidence Limit | P  |
|----------------------------------------------------|------------|---------------------------|---------------------------|----|
| Anticipated high likelihood of inotrope dependence | 1.80       | 0.21                      | 15.61                     | .595|

*Model is adjusted for age, sex, cause of heart failure, history of ventricular tachycardia, admission systolic blood pressure, admission creatinine level, inotrope choice, arrhythmias on inotrope therapy, and days on inotrope therapy.*
CONCLUSION

Hemodynamically stable patients with HF initiated electively on IIT to augment diuresis during hospitalization are at high risk for adverse outcomes. Only 53% of patients (n=49) were discharged alive and without hospice or IIT at home. The high rate of poor outcomes coupled with the limited ability of clinical data and attending providers to identify the highest risk patients underscores the importance of proactive advanced care planning. In this study, only 51% of patients (n=47) had a goals-of-care conversation before the initiation of inotrope treatment, highlighting a significant opportunity for quality and clinical improvement.

ABBREVIATIONS AND ACRONYMS: ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; ESCAPE = Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; HF = heart failure; IIT = intravenous inotropic therapy; IQR = interquartile range; VAD = ventricular assist device

AFFILIATIONS (CONTINUED FROM THE FIRST PAGE OF THIS ARTICLE): Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA (M.N., N.M.L.); Division of Cardiology, University of Colorado School of Medicine, Aurora (D.S.R.); Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (A.R., O.A.); Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (L.W.S.); Dartmouth-Hitchcock Medical Center, Heart and Vascular Center (L.G.G.), and The Dartmouth Institute, Geisel School of Medicine at Dartmouth, Lebanon, NH (L.G.G.).

GRANT SUPPORT: This study was supported by National Institutes of Health/National Heart, Lung and Blood Institute Heart Failure Research Network, U10-HL110337. Dr Gilstrap is also supported by K23-HL142835. Dr Nayor is also supported by K23-HL138260.

POTENTIAL COMPETING INTERESTS: Dr. Snipelisky is on the Speaker’s Bureau for Pfizer, Inc. Dr Fudim consults for Coridea, Axon Therapies, and Galvani Bioelectronics. The other authors report no competing interests.

REFERENCES

1. Gilstrap LG, Snipelisky D, AbouEzzeddine O, et al. Unanswered questions in contemporary heart failure. J Card Fail. 2017;23(10):770-774.
2. Ginwalla M, Tofovic DS. Current status of inotropes in heart failure. Heart Fail Clin. 2018;14(4):601-616.
3. Fares WH. Management of acute decompensated heart failure in an evidence-based era: what is the evidence behind the current standard of care? Heart Lung. 2008;37(3):173-178.
4. Cooper LB, Hammill BG, Sharma PP, et al. Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. Am Heart J. 2015;170(6):1124-1132.
5. Kang J, Cho HJ, Lee HY, et al. Effects of widespread inotrope use in acute heart failure patients. J Clin Med. 2018;7(10):368.
6. Kalogeropoulou AP, Marti CN, Georgiopoulou VV, Butler J. Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and ejection fraction. J Card Fail. 2020;26(8):593-601.
7. Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure. Circ Heart Fail. 2015;8(5):880-886.
8. Mebazaa A, Motiejunaite J, Gayat E, et al; ESC Heart Failure Long-Term Registry Investigators. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail. 2018;20(3):332-341.
9. Guglin M, Kaufman M. Inotropes do not increase mortality in advanced heart failure. Int J Med Gen. 2014;7:237-251.
10. Katz JN, Waters SB, Hollis IB, Chang PP. Advanced therapies for end-stage heart failure. Circ Cardiovasc Qual Outcomes. 2015;8(1):63-72.
11. Dana S, Marasco RA, Sengson S. Outcomes Based Therapeutic Interchange: An ACE Inhibitor Interchange Program. Alexandria, VA: American Society of Consultant Pharmacists, Inc; 1999.
12. Allen LA, Fanarow GC, Grau-Sepulveda MV, et al; American Heart Association’s Get With The Guidelines Heart Failure Investigators. Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines. Circ Heart Fail. 2014;172:251-260.
13. Elkayam U, Tassia G, Binany C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153(1):98-104.
14. Snipelisky D, Ray J, Matcha G, et al. Mayo Registry for Telemetry Efficacy in Arrest (MR TEA) study: an analysis of code status following cardiopulmonary arrest resuscitation. 2015;92:14-18.